The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of pralsetinib in RET fusion-positive solid tumors: Final data from the ARROW trial.
 
Vivek Subbiah
Consulting or Advisory Role - AADi; Abbvie (Inst); Bayer (Inst); Foundation Medicine; Illumina; Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Other Relationship - Clinical Care Options; Medscape
 
Philippe Cassier
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; OSE Immunotherapeutics; Scenic Biotech; START
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Agenus; AstraZeneca; Bayer; Bristol-Myers Squibb; CheckmAb; Daiichi Sankyo; GlaxoSmithKline; Merck; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Seagen; T-One Therapeutics
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Elena Garralda
Employment - Next Oncology
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; Amgen; Anaveon; Astex Pharmaceuticals; Boehringer Ingelheim; Daiichi Sankyo/Lilly; Ellipses Pharma; Genmab; Gilead Sciences; Greywolf; Hengrui Therapeutics; Incyte; Janssen; Marengo Therapeutics; Medpace; Medscape; Pfizer; Roche; Sanofi; Seagen; Skypta; Sotio
Speakers' Bureau - AEFI; Alcura; Aran; AstraZeneca; CDDF; Doctaforum; ESMO; Fundación ECO; Fundación SEOM; Horizon CME; Karger Publishers; Medscape; MeetingPharma; MSD; Novartis; PPD Global; Roche; Seagen; Springer Nature; Tactics; The Ricky Rubio Fundation
Research Funding - Anaveon; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Pilar Garrido
Employment - Teva (I)
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Daiichi Sankyo Europe GmbH; Gebro Pharma (I); IO Biotech; Janssen Oncology; MSD Oncology; Nordic Group (I); Pfizer; PharmaMar; Pierre Fabre; Regeneron; Roche Pharma AG
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; Lilly; Pfizer
Travel, Accommodations, Expenses - AstraZeneca Spain; Johnson & Johnson/Janssen; Roche Pharma AG
Other Relationship - IO Biotech; Janssen Oncology; Novartis
 
Ernest Nadal
Honoraria - Apollomics; Roche/Genentech; Transgene
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Genmab; Janssen Oncology; Lilly; Merck Serono; MSD; Pfizer; Pierre Fabre; Qiagen; Roche; Sanofi; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Takeda
 
Jacqueline Vuky
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Fortis (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Gilberto Lopes
Stock and Other Ownership Interests - Biomab; CDR-Life; Lucence Diagnostics; Morphometrix; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Dr. Reddy's Laboratories; Janssen; Merck; Rigel
Consulting or Advisory Role - AstraZeneca; Coherus Biosciences; Dr. Reddy's Laboratories; Mirati Therapeutics; Pfizer; Regeneron
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; BeiGene; Boehringer Ingelheim; Celgene; Coherus Biosciences; Dr. Reddy's Laboratories; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
 
Gregory Kalemkerian
Consulting or Advisory Role - BioMed Valley Discoveries (I)
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb Foundation (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck (Inst); Takeda (Inst)
 
Daniel Bowles
No Relationships to Disclose
 
Mahesh Seetharam
No Relationships to Disclose
 
Martin Schuler
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson/Janssen; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunocore; Johnson & Johnson/Janssen; MSD; Novartis; Regeneron; Roche; Sanofi; Tacalyx
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Yun Fan
No Relationships to Disclose
 
Amber Thomassen
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Sophia Wang
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech